INCY 241220 45.00P (INCY241220P45000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

INCY241220P45000

Watchlist

0.55
0.000.00%

15min DelayTrading May 21 11:09 ET

0.00High0.00Low

Intraday

5D
Daily

News

Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Kevin Travers11:21 ET
Positive Outlook on Incyte's Stock: InMIND Study Validates Tafasitamab Combination Efficacy and Safety
TipRanksDec 12 02:07 ET
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Kevin TraversDec 11 10:47 ET
Market Falls Wednesday, but Googles Chip Impresses | WST
Kevin TraversDec 10 16:19 ET
Incite Says Phase 3 Trial of Monjuvi in Follicular Lymphoma Patients Meets Endpoints
MT NewswiresDec 10 11:27 ET
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Kevin TraversDec 10 10:51 ET

Comments

韭菜变主力

Nov 19 12:59

$Merck & Co (MRK.US)$ $Incyte (INCY.US)$ is a great company. Buying it would be a good decision, unless Merck massively overpays.

The Thinker

Oct 29 19:14

Tech Stocks Surge While Dow Falters as U.S. Markets Prepare for Key Data

Click Here: TYNKR LAB™
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...

🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...

Trytosaveabit

Aug 14 16:41

News

$Syndax Pharmaceuticals (SNDX.US)$ $Incyte (INCY.US)$ Reuters
5 mins ago
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (Axatilimab-Csfr) for the Treatment of Chronic Graft-Versus-Host Disease (Gvhd)